DNA damage, oxidative stress, and inflammation in children with celiac disease

Abstract

The objective of this study was to evaluate the level of genomic instability in patients with celiac disease and to establish a relationship between inflammation, oxidative stress, and DNA damage in these patients. Myeloperoxidase (MPO) activity, adenosine deaminase, nitric oxide (NOx), thiobarbituric acid, catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx), and DNA damage were evaluated in peripheral blood samples from 47 celiac disease patients and 31 controls. Patients with celiac disease presented higher levels of DNA damage in comparison to controls (p=0.023). This difference was also observed for markers of oxidative stress, such as CAT (p=0.011) and SOD (p=0.013), and inflammatory markers such as MPO (p < 0.001) and NOx (p=0.009). Positive correlations were found between DNA damage levels and the values of CAT (r=0.405; p=0.009) and SOD (r=0.516; p < 0.001). Positive correlations were also found between GPx and NOx (r=0.349; p=0.030) and MPO and NOx (r=0.239; p=0.039). CAT and NOx showed a negative correlation (r= −0.315; p=0.042). In conclusion, intestinal inflammation can have systemic effects, causing an imbalance between oxidant and antioxidant markers, which may promote increased levels of DNA damage.

Keywords:
Celiac disease; biochemical markers; genotoxicity; reactive oxygen species (ROS); inflammatory markers

Introduction

Celiac disease (CD) is a chronic inflammatory condition of the small intestine caused by a reaction to gluten exposure. There are many genetic and environmental factors that can interact to cause the disease (Sollid and Jabri, 2005; Van Heel and West, 2006). Histologically, the affected small intestine presents with villous atrophy, crypt hypertrophy, flat mucosa, and intraepithelial lymphocytosis, which leads to malabsorption of micro- and macronutrients (Bottaro et al., 1999; Murray, 1999). The treatment for CD is a gluten-free diet (GFD), which, in most cases, leads to the disappearance of symptoms. A GFD also prevents other autoimmune diseases, osteoporosis, and gastrointestinal cancer, which are CD-related conditions that may occur (Wright, 1995; Ryan and Kelleher, 2000).

Some gliadin peptides possess the ability to penetrate cells by endocytosis (Schumann et al., 2008; Heyman and Menard, 2009). Peptide accumulation in lysosomes leads to increased levels of reactive oxygen species (ROS) (Zimmer et al., 2010). In addition to ROS, reactive nitrogen species (RNS) are also referred to as oxidants due to their ability to remove electrons from biological molecules, thus promoting a nitrosative stress (Halliwell and Gutteridge, 2007). When oxidizing compounds are high in relation to antioxidant defenses oxidative stress occurs, either due to increased ROS and RNS or decreased antioxidant defenses. Antioxidant defenses can come from endogenous sources such as catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione reductase (GSR), and reduced glutathione (GSH), and dietary sources, such as vitamins, minerals, and polyphenols (Halliwell and Gutteridge, 2007; Kerasioti et al., 2017). SOD catalyzes the conversion of the superoxide anion (O₂^•-) into hydrogen peroxide (H₂O₂), while CAT reduces H₂O₂ to water (H₂O) and oxygen (O₂). GPxs, in turn, are able to reduce H₂O₂ and lipid hydroperoxides by oxidizing GSH into oxidized glutathione, and subsequently, GSR can regenerate GSH (Halliwell and Gutteridge, 2007; Kerasioti et al., 2017).

Studies have shown that oxidative stress is one of the mechanisms that can play a role in gliadin toxicity. Gliadin, a class of proteins present in wheat, can trigger oxidative stress and induce the release of pro-inflammatory cytokines (Shan et al., 2002; Ciccocioppo et al., 2005). ROS can lead to a subsequent DNA damage (Cooke et al., 2006). Chronic inflammation can be linked to carcinogenesis and it has been reported that it may be involved in the development of about one third of all cancer cases (Ames et al., 1993; Coussens and Werb, 2002). In this regard, patients with celiac disease have an increased risk of cancer (Han et al., 2015).

There is evidence that DNA damage may be used as a predictive marker of cancer development (Olinski et al., 2003). Single cell gel electrophoresis (SCGE), also known as the comet assay, provides a reliable method for assessing DNA damage quantitatively in single cells. It requires viable but not growing interphase cells, and can be applied to terminally differentiated cells (Ross et al., 1995). Lymphocytes are excellent cells to analyze markers of DNA damage exposure because they circulate for years or even decades through different organs and accumulate DNA damage during their lifespan (Natarajan and Obe, 1980; Carrano and Natarajan, 1988). Much evidence has been generated about the association of micronucleus induction (Murgia et al., 2008) and DNA damage detected by the comet assay (Gunasekarana et al., 2015) with the development of cancer.

The overall objective of this study was to evaluate biochemical markers of inflammation, nitro-oxidative stress, and levels of DNA damage in peripheral blood of patients with celiac disease. Several studies have demonstrated the increase of oxidative stress in celiac disease (Ciccocioppo et al., 2005; Kerasioti et al., 2017). Here, we assessed the correlation of inflammatory markers with increased levels of DNA damage, evidenced through the comet assay.

Subjects and Methods

Subjects

Blood samples from 47 patients with CD who attended the Hospital Infantil Joana de Gusmão (HIJG), Florianopolis in Southern Brazil, were collected. The patient group consisted of 18 boys and 29 girls, with a mean age of 7.12 ± 2.76 years. The control group consisted of 12 boys and 19 girls, with a mean age of 6.42 ± 2.33 years (Figure 1). For the patient group, the samples were collected at the moment of first endoscopy with biopsy for diagnosis of CD and the patients were included in the study after the confirmation of the diagnosis. No child was being treated with medications and none was obese or overweight. The control group was composed by healthy children who were referred for routine examinations and whose parents agreed to participate in this study. This work represents a prospective, case-control study. This study was approved by the Research Ethic Committee of the Universidade Federal de Santa Catarina, SC, Brazil. A written informed consent form was read and signed by the legal guardians of all study participants, who received a copy of the consent form with general information about the study signed by the principal investigator.

Figure 1
Study flow chart.

Three tubes (4 mL) of blood were collected from each individual: one with heparin (protected from light) for the analysis of DNA damage, one with EDTA for analysis of oxidative stress, and one without anticoagulant (with separating gel), for the analysis of inflammatory markers. All samples were immediately centrifuged after collection and serum was placed in liquid nitrogen for further analysis.

Quantification of myeloperoxidase activity (MPO)

MPO activity in blood samples was measured according to the method developed by Rao et al. (1993). Briefly, standard samples with different concentrations of myeloperoxidase (from human neutrophils, Sigma: M6908) were prepared in order to obtain a standard curve in the range of 0.07–140 mlU/mL. Serum aliquots (40 μL) and standards were transferred to cuvettes and the reaction was initiated with the addition of 360 μL of assay buffer (0.167 mg/mL of o-dianisidine 2HCL and 0.0005% H₂O₂). The reaction was stopped with 1% sodium azide. Subsequently, the samples were centrifuged at 50 g for 5 min, the supernatants were separated, and absorbance change rates (450 nm) were determined on an ELISA plate reader (Saleh et al., 1996). Myeloperoxidase activity was estimated by interpolation from the standard curve described above. Results are reported as mIUmL⁻¹.

Quantification of adenosine-deaminase activity (ADA)

Initially, standard samples (final volume of 500 μL) with different volume concentrations of NaH₂PO₄H₂O (35 mM), Na₂HPO₄H₂O (15 mM), and NH₃SO₄ (15 mM) were prepared to obtain a standard curve in the range of 10–50 U/L. Serum samples (20 μL) were transferred to cuvettes, and a reaction was initiated by the addition of adenosine phosphate buffered solution (pH 6.5, 500 μL, composition: NaH₂PO₄H₂O (35 mM), Na₂HPO₄12H₂O (15 mM), and adenosine (0.5 mM). After incubation for 1 h at 37 °C, the reaction was stopped by the addition of 1000 μL of phenol solution (1 mM), nitroprussiate (0.17 mM), and alkaline buffer (1 mL NaOCl, 11 mM). This solution (final volume 2 mL) was also added to the cuvettes with the different standard samples. Afterward, the absorbance change at 620 nm was determined. ADA activity was estimated by interpolation from the standard curve by colorimetric measurements in an ELISA plate reader (Organon Teknika, Roseland, NJ, USA) (Giusti and Galanti, 1984). Results are reported in U/L.

Quantification of nitrate/nitrite levels (NOx)

Quantification of the nitric oxide products in the serum was carried out according to the methodology described by Green et al. (1982). Fluid samples (0.1 mL) were transferred to cuvettes, and 0.05 M vanadium chloride (0.15 mL) in 1.0 M HCl (0.05 mL) was added to reduce nitrate to nitrite. Immediately, Griess reagent (150 μL of 0.004 M naphthyl ethyl endiamide dihydrochloride in H₂O and 0.06 M sulphanilamide (150 μL) in 0.03 M H₃PO₄, vol. 1:1) were added. After incubation at 37 °C for 45 min, the reaction was transferred to a microplate. Nitrite concentrations were estimated by interpolation from a standard curve of sodium nitrite (0-150 μM) by colorimetric measurements at 540 nm in an ELISA plate reader (Organon Tecknika, Roseland, New Jersey, USA). Results are reported as μM.

Quantification of lipoperoxidation levels (TBARS)

The endogenous lipid oxidation was evaluated in the plasma by determination of thiobarbituric acid-reactive substances (TBARS) according to the method described by Bird and Draper (1984). In this protocol, products of lipid peroxidation react with thiobarbituric acid producing a pink Schiff base that was measured spectrophotometrically at 535 nm, in an UV/Visible spectrophotometer GBC-916 (GBC Scientific Equipment, Dandenong, Australia). Concentrations were expressed as mmol of TBARS/mL.

Quantification of antioxidant enzymes

Catalase activity

The catalase (CAT) activity was determined in whole blood according to the methodology described by Aebi (1984). The reaction is based on the breakdown of hydrogen peroxide (dissolved on phosphate buffer: mmol: NaCl 137, KCl 2.7 and phosphate buffer salts 10) in the presence of the enzyme (CAT) in the blood resulting in the decrease of a freshly prepared H₂O₂ solution (10 mM). CAT activity was measured as the change in optical density for 3 min at 240 nm in a UV/Visible spectrophotometer GBC-916 (GBC Scientific Equipment, Dandenong, Australia). Enzyme activity was expressed as mmolmin⁻¹mL⁻¹.

Superoxide dismutase activity

Superoxide dismutase (SOD) activity was analyzed in whole blood in accordance with the method described by Misra and Fridovich (1972) and modified by Boveris et al. (1983). This reaction is based on the epinephrine oxidation (pH 2.0 to pH 10.0) produced by superoxide anion from the xanthine/xanthine oxidase system that generates a pink chromophore named formazan. In this protocol, the epinephrine-adrenochrome transition is inhibited by superoxide dismutase present in the blood. Absorbance was monitored for 3 min at 480 nm in a UV/Visible spectrophotometer. The arbitrary unit of the enzyme activity was expressed as 50% of auto-oxidation inhibition of epinephrine-adhenochrome formation.

Glutathione peroxidase activity

Glutathione peroxidase (GPx) activity was analyzed in whole blood using the method described by Flohe and Gunzler (1984). Briefly, this method is based on the tertbutyl hydroperoxide (t-BuOOH) dismutation via oxidation of reduced glutathione (GSH) to oxidized glutathione (GSSG). This oxidation is further catalyzed by GPx resulting in the decrease of absorbance that was evaluated at 340 nm in a UV/Visible spectrophotometer. In this protocol, to avoid over-evaluation of the enzyme activity due to the hemoglobin oxidation present in the blood, 50 mM of KCN was added to the cuvette. The unit of enzyme activity was μmolmin⁻¹mL⁻¹.

Comet assay

The comet assay protocol was described by Singh et al. (1988). The assay was carried out as described for in vivo samples (Tice et al., 2000; Hartmann et al., 2003). Blood samples were mixed with low-melting point agarose, spread onto agarose-precoated slides, gently covered with cover slips and placed in a cold tray. Once the samples had solidified, the cover slips were removed and the slides left to stand in lysis buffer (2.5 M NaCl, 100 mM EDTA, 10 mM Tris, pH 10.2, to which 1% Triton X-100 and 10% DMSO were added) for 1 or 2 days, under refrigeration. Excess fluid was removed from each slide and all slides were placed in an electrophoresis tank to which a basic solution (300 mM NaOH, 1 mM EDTA, pH > 13) was added. Slides were left to stand in this solution for 20 min to enable unwinding of DNA and expression of alkali-labile sites and single-strand breaks. Electrophoresis was then run for 20 min at 25 V, 300 mA, and 0.9 V/cm. Slides were removed from the electrophoresis tank, washed three times in neutralizing solution (0.4 M Tris, pH 7.5), rinsed three times with distilled water, and left to dry at room temperature. All procedures subsequent to blood collection were carried out in the absence of light. Slides were then fixed and silver-stained as described by Nadin et al. (2001). For assessment of DNA damage, 100 cells per sample were examined under light microscopy (x200 magnification). Cells were scored on a scale of 0 (no migration) to 4 (maximal migration) according to tail intensity (dimensions and shape) (Figure 2). Therefore, the total sum of damage scores for a sample of 100 cells (the damage index) ranged from 0 (no migration in any cell) to 400 (maximal migration in all cells). Patient and control slides were processed and analyzed together (Bagatini et al., 2008; Maluf et al., 2009).

Figure 2
Comet assay: nuclei of leucocytes exhibiting different levels of DNA damage. A: score 0 (no migration); B: score 1; C: score 2; D: score 3, and E: score 4 (maximal migration).

The cytokinesis-block micronucleus (CBMN) assay

For the CBMN assay, an aliquot of blood (0.5 mL) was added to 5 mL of RPMI 1640 medium supplemented with 20% fetal calf serum and 0.2% phytohemagglutinin. The culture flasks were incubated at 37 ºC for 44 h after which 4.5-μg/mL cytochalasin B was added. Twenty-eight hours later (72 hours of culture), the material was harvested according to the method described by Fenech and Morley (1985) and revised by Fenech and Crott (2002). The cell suspension was fixed in 3:1 methanol:acetic acid and dropped onto clean slides. The slides were then stained with Giemsa. One thousand binucleate cells from each individual were scored for micronuclei (MN), nucleoplasmic bridges (NB between daughter nuclei), and nuclear buds (BUD) (amplified DNA) (Figure 3) on slides identified by a code for blinded analysis.

Figure 3
Nuclear abnormalities detected by micronuclei test (arrows). (A) micronucleus; (B) nuclear bud; (C) nucleoplasmic bridge.

Statistical analysis

Results are presented as mean and standard deviation. Comparisons between groups were done using two-tailed Student's t-tests when the results followed a normal distribution, and the Mann-Whitney U-test was used when the results did not follow a normal distribution. Correlations between linear variables, such as the biochemical and DNA damage markers, were analyzed by Spearman's rank test. Statistical analysis was performed using SPSS 18.0, with a minimal level of significance of 0.05.

Results

DNA damage levels detected by the comet assay were increased (p=0.023) in celiac patients (20.57 ± 10.59) when compared to controls (11.36 ± 6.42).

The frequency of micronuclei and nuclear buds were also increased in patients (6.66 ± 4.46 and 4.82 ± 3.90, respectively) when compared to controls (2.44 ± 2.14 and 2.60 ± 2.66, respectively) (p < 0.001 and p=0.007, respectively). There was no statistically significant difference between the frequency of nucleoplasmic bridges evaluated in patients and controls.

As for markers of oxidative stress, CAT and SOD activities showed significant differences between patients (10.17 ± 2.79 and 74.34 ± 22.23, respectively) and controls (6.48 ± 2.38 and 58.23 ± 23.29, respectively) (p=0.011 and p=0.013, respectively). However, GPx activity and lipoperoxidation levels measured as TBARS did not present statistic differences between celiac patients and controls.

The inflammatory markers MPO (938.21 ± 352.53) and NOx (54.32 ± 44.82), but not ADA, also showed increased values in patients in relation to controls (195.47 ± 39.84 and 31.15 ± 8.37, respectively) (p > 0.001 and p=0.009, respectively) (Table 1).

Table 1
Markers of oxidative stress, inflammation and DNA damage in patients with celiac disease and controls.

	Celiac disease	Controls	p
TBARS	0.060 ± 0.059 (n=47)	0.0433 ± 0.0432 (n=31)	NS
CAT	10.17 ± 2.79 (n=45)	6.48 ± 2.38 (n=20)	0.011
SOD	74.34 ± 22.23 (n=47)	58.23 ± 23.29 (n=20)	0.013
GPx	50.23 ± 8.98 (n=42)	53.13 ± 17.74 (n=20)	NS
MPO	938.32 ± 352.53 (n=47)	195.47 ± 39.84 (n=31)	< 0.001
ADA	13.06 ± 6.16 (n=46)	11.82 ± 2.14 (n=31)	NS
NOx	54.32 ± 44.82 (n=43)	31.15 ± 8.37 (n=31)	0.009
Comet	20.57 ± 10.59(n=44)	11.36 ± 6.42 (n=20)	0.023
MN	6.66 ± 4.46 (n=44)	2.44 ± 2.14 (n=25)	< 0.001
NPB	1.09 ± 1.18 (n=44)	0.92 ± 1.08 (n=25)	NS
BUD	4.82 ± 3.90 (n=44)	2.60 ± 2.66 (n=25)	0.007

• Mean ± standard deviation. TBARS: Measure of substances that react with thiobarbituric acid; CAT: activity of catalase; SOD: superoxide dismutase activity; GPx: glutathione peroxidase activity; MPO: myeloperoxidase activity; ADA: adenosine deaminase; NOx: nitrogen oxides; Comet: Index of damage measured in 100 cells per individual; MN: micronucleus, NPB: nucleoplasmic bridge and BUD: nuclear buds, in 1000 cells per individual; P: significance level, NS: not statistically significant, n: number of subjects.

The relationship between different biomarkers was tested. DNA damage measured by the comet assay was correlated with CAT (r=0.405; p=0.009) and SOD activity (r=0.516; p < 0.001), and with the micronuclei frequency (r=0.77; p < 0.01). Positive correlations were also found between CAT and NOx (r= −0.315; p=0.042), GPx and NOx (r=0.349; p=0.030), and MPO and NOx (r=0.239; p=0.039).

Discussion

When comparing patient and control groups, we found statistically significant differences in the contents of DNA damage assessed by the comet assay, as well as in the micronuclei and BUD frequencies that are genomic instability markers. Regarding the oxidative stress markers, CAT and SOD presented higher activity in CD patients, and as for the inflammation markers, MPO was lower and NOx was higher in patients compared to controls. The other markers analyzed in this study showed no statistically significant differences between patients and controls.

Pro-oxidative processes and inflammatory conditions are present in many diseases, including CD. It is well known that inflammation is associated with enhanced nitric oxide (^•NO) levels, consequently leading to increased RNS and ROS generation (Ferretti et al., 2012).

Accordingly, some studies suggest that gluten can generate oxidative stress (Szaflarska-Poplawska et al., 2010; Ferretti et al., 2012), although Szaflarska-Poplawska et al. (2010), analyzing urinary excretion of 8-oxodG and 8-oxo-Gua, have concluded that it may not be only the gluten that causes oxidative stress, and that there is a factor independent of diet. Cellular and tissue responses can be triggered by xenobiotics or endogenous compounds that act as a stimulus for inflammatory processes and oxidative stress. In CD, gluten is the agent that triggers the immune process that results in inflammation. Alfa-gliadin peptides enter the cell by endocytosis and accumulate in lysosomes, leading to the activation of signal transduction pathways and increasing the levels of ROS and RNS (Zimmer et al., 2010).

Nitro-oxidative stress induced by gluten is involved in the activation of the transcription factor NF-κB that induces transcription of cytokines and enzymes, such as COX2 and iNOS, with consequent production of prostaglandins, ^•NO metabolites, lipid hydroperoxides and other oxidative stress markers (Ferretti et al., 2012).

As a consequence, CD patients usually reveal elevated ^•NO levels both in serum and urine (Koster-Kamphuis et al., 2003; Ertekin et al., 2005), while evidence indicates that ^•NO is also a regulator of intestinal inflammation (e.g., Kolios et al., 2004). Therefore, CD is the result of a combination of severe nitro-oxidative stress associated with a chronic inflammatory process (Halliwell and Gutteridge, 2007). Accordingly, as mentioned before, in the present study we detected elevated NOx levels, as indirect measure of ^•NO metabolites, which is an important participant in the inflammatory process (Lam et al., 2015). The activity of MPO was enhanced approximately five times in CD patients, which is also responsible for exacerbation of the disease (Ferretti et al., 2012). Interestingly, MPO activity as well as levels of TNF-α are higher in colitic rats compared to normal animals, while the treatment with an inflammatory plant extract was able to reduce such inflammatory markers (Abiodun and Oshinloye, 2017), revealing the importance of antioxidant supplementation in attenuating such condition.

In the present study SOD and CAT activity were up-regulated, nevertheless such increase apparently was not sufficient to prevent or even attenuate the systemic oxidative stress detected in CD patients. The positive correlations found between levels of DNA damage and SOD and CAT activities probably reflect the close interdependence of these two important antioxidant enzymes in counteracting the initial reactions of ROS generation, i.e., the formation of superoxide anion (O₂^•-) and hydrogen peroxide (H₂O₂), respectively. Therefore, they are able to attenuate the related nitrosative damage to important biomolecules and tissues promoted by the hydroxyl radical (^•OH) generated by the Fenton/Haber-Weiss reactions (Wilhelm Filho et al., 2000; Halliwell and Gutteridge, 2007).

Interestingly, and contrary to other studies, GPx activity was not altered compared to controls in the present study. A high GPx activity is generally found together with a high rate of peroxide production, as in erythrocytes of healthy subjects (Brigelius-Flohe, 1999). Taking into account that in the present study the TBARS contents found in plasma were not different in CD patients compared to controls, such maintenance of GPx activity could be justified. However, a positive correlation was found between GPx activity and NOx levels, despite relatively weak (r=0.349; p=0.030).

In a related study on the blood of CD patients, Stojiljkovic et al. (2007) found a marked increase in SOD activity, while GPx was significantly decreased. When measured in samples harvested from the small intestinal biopsies from CD children, SOD activity was also elevated, while the activities of GPx and GSR, as well as GSH levels were significantly decreased, thus showing an impairment of GSH-dependent enzymes (Stojiljkovic et al., 2009). High levels of lipid oxidation (measured as TBARS levels) were found in the blood as well as in the small intestine mucosa of CD children in other related studies (Odetti et al., 1998; Stojiljkovic et al., 2009) respectively). All these results clearly indicate that the oxidative stress detected in the intestine mucosa is reflected in the blood of CD patients.

In addition to the consequences of ROS over-generation in CD as mentioned above, oxidative stress can also lead to higher rates of DNA damage. Misrepaired or nonrepaired DNA lesions result in mutations, which increase cancer risk. Chronic inflammation is strongly associated to human tumors, and one-fifth of all cancers have their formation route related to inflammation (De Marzo et al., 2007).

Research in the area has shown that oxidative stress, chronic inflammation, DNA damage, and cancer are closely related conditions (Cooke et al., 2006; Ferretti et al., 2012; Ferguson et al., 2015). Somatic mutations have been identified as causing neurological diseases (Poduri et al., 2013) and other autoimmune diseases (Ross, 2014), in addition to cancer. Han et al. (2015), in a meta-analysis study, concluded that celiac patients have increased risk of all malignancies, including esophageal cancer and small intestine carcinoma, while Peters et al. (2003) showed an increased risk for non-Hodgkin's lymphoma and T cell adenocarcinoma of the small intestine in a Swedish cohort of celiac patients.

The first course of action after the diagnosis of celiac disease is establishing a gluten-free diet, which greatly improves the clinical symptoms of most patients (Pham-Short et al., 2016). However, after this improvement in quality of life, patients begin to suffer from the specter of cross-contamination (See et al., 2015), which is almost inevitable, taking into account the strong culture of wheat consumption of the western civilization. Celiac patients can have iron deficiency anemia (Rodrigo, 2006), because the absorption of iron is made in the proximal small intestine, which appears impaired in celiac disease. Szaflarska-Poplawska et al. (2010) postulated that control of oxidative stress and DNA damage found in the cells of celiac patients depends not only on gluten-free diet. They studied 8-oxodG levels and the mean plasma retinol and α-tocopherol concentrations in celiac patients and suggested a diet with vitamin supplementation to reduce cancer risk. CD is a condition caused by many factors. The undisputedly important environmental factor is gluten. The inflammatory process can lead to the development of cancer, but we have to consider that cancer is also influenced by several factors, and the individual's DNA repair capacity is one of the main factors. Therefore, patients with CD and DNA repair deficiency may be those most likely to develop cancer.

Therefore, taking into consideration the result of this study, it is highly suggested that patients supplement their diet with antioxidants and antimutagens, which can minimize the deleterious consequences of ROS over-generation associated with inflammation processes (Sram et al., 2012; Ferguson et al., 2015), eventually keeping the patient away from the threat of cancer onset or other diseases secondary to CD.

Another set of people who can benefit from dietary supplementation, are celiac relatives who carry the DQ2 and DQ8 genes and, therefore, may develop celiac disease. Avoiding oxidative stress, perhaps intestinal inflammation may not even start. As a consequence, supplementation with vitamins and minerals is highly recommended in such circumstances (Ferguson and Fenech, 2012).

The present study demonstrated that the inflammatory process and the systemic oxidative stress detected are closely related with DNA damage in CD patients. To avoid or attenuate such condition, removing the antigen (gluten), as well as counteracting ROS over-generation with an antioxidant intervention, might be key for CD treatment.

Acknowledgments

We thank all the volunteers who participated in the study. This work was financially supported by the Conselho Nacional de Pesquisa (CNPq), agency of the Ministry of Science, Technology and Innovation, and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior” (CAPES Brasil – Finance code 001), agency of the Ministry of Education, Government of Brazil [grant numbers 307810/2012-7; 150640/2011-0; 303234/2015-6].

References

• Abiodun OO and Oshinloye AO (2017) Carpolobia lutea G. Don (Polygalaceae) inhibits inflammation and oxidative stress in an acetic acid induced model of rat colitis. Drug Res (Stuttg) 67:20-24.
• Aebi H (1984) Catalase in vitro Methods Enzymol 105:121-126.
• Ames BN, Shigenaga MK and Hagen TM (1993) Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A 90:7915-7922.
• Bagatini PB, Palazzo RP, Rodrigues MT, Costa CH and Maluf SW (2008) Induction and removal of DNA damage in blood leukocytes of patients with type 2 diabetes mellitus undergoing hemodialysis. Mutat Res 657:111-115.
• Bird RP and Draper HH (1984) Comparative studies on different methods of malonaldehyde determination. Methods Enzymol 105:299-305.
• Bottaro G, Cataldo F, Rotolo N, Spina M and Corazza GR (1999) The clinical pattern of subclinical/silent celiac disease: an analysis on 1026 consecutive cases. Am J Gastroenterol 94:691-696.
• Boveris A, Fraga CG, Varsavsky AI and Koch OR (1983) Increased chemiluminescence and superoxide production in the liver of chronically ethanol-treated rats. Arch Biochem Biophys 227:534-541.
• Brigelius-Flohe R (1999) Tissue-specific functions of individual glutathione peroxidases. Free Radic Biol Med 27:951-965.
• Carrano AV and Natarajan AT (1988) International Commission for Protection Against Environmental Mutagens and Carcinogens. ICPEMC publication no. 14. Considerations for population monitoring using cytogenetic techniques. Mutat Res 204:379-406.
• Ciccocioppo R, Di Sabatino A and Corazza GR (2005) The immune recognition of gluten in coeliac disease. Clin Exp Immunol 140:408-416.
• Cooke MS, Olinski R and Evans MD (2006) Does measurement of oxidative damage to DNA have clinical significance? Clin Chim Acta 365:30-49.
• Coussens LM and Werb Z (2002) Inflammation and cancer. Nature 420:860-867.
• De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB and Nelson WG (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7:256-269.
• Ertekin V, Selimoglu MA, Turkan Y and Akcay F (2005) Serum nitric oxide levels in children with celiac disease. J Clin Gastroenterol 39:782-785.
• Fenech M and Morley AA (1985) Measurement of micronuclei in lymphocytes. Mutat Res 147:29-36.
• Fenech M and Crott JW (2002) Micronuclei, nucleoplasmic bridges and nuclear buds induced in folic acid deficient human lymphocytes-evidence for breakage-fusion-bridge cycles in the cytokinesis-block micronucleus assay. Mutat Res 504:131-136.
• Ferguson LR and Fenech MF (2012) Vitamin and minerals that influence genome integrity, and exposure/intake levels associated with DNA damage prevention. Mutat Res 733:1-3.
• Ferguson LR, Chen H, Collins AR, Connell M, Damia G, Dasgupta S, Malhotra M, Meeker AK, Amedei A, Amin A et al. (2015) Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Semin Cancer Biol 35 Suppl:S5-S24.
• Ferretti G, Bacchetti T, Masciangelo S and Saturni L (2012) Celiac disease, inflammation and oxidative damage: A nutrigenetic approach. Nutrients 4:243-257.
• Flohe L and Gunzler WA (1984) Assays of glutathione peroxidase. Methods Enzymol 105:114-121.
• Giusti G and Galanti B (1984) Adenosine deaminase: Colorimetric method. In: Bergmeyer HU (ed) Methods of Enzymatic Analysis. Verlag Chemie, New York, pp 315-323.
• Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS and Tannenbaum SR (1982) Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 126:131-138.
• Gunasekarana V, Raj GV and Chand P (2015) A comprehensive review on clinical applications of comet assay. J Clin Diagn Res 9:Ge01-Ge05.
• Halliwell B and Gutteridge JMC (2007) Free Radicals in Biology and Medicine. 4th edition. Clarendon, Oxford, 704 p.
• Han Y, Chen W, Li P and Ye J (2015) Association between coeliac disease and risk of any malignancy and gastrointestinal malignancy: A meta-analysis. Medicine (Baltimore) 94:e1612.
• Hartmann A, Agurell E, Beevers C, Brendler-Schwaab S, Burlinson B, Clay P, Collins A, Smith A, Speit G, Thybaud V et al. (2003) Recommendations for conducting the in vivo alkaline Comet assay. 4th International Comet Assay Workshop. Mutagenesis 18:45-51.
• Heyman M and Menard S (2009) Pathways of gliadin transport in celiac disease. Ann N Y Acad Sci 1165:274-278.
• Kerasioti E, Terzopoulou Z, Komini O, Kafantaris I, Makri S, Stagos D, Gerasopoulos K, Anisimov NY, Tsatsakis AM and Kouretas D (2017) Tissue-specific effects of feeds supplemented with grape pomace or olive oil mill wastewater on detoxification enzymes in sheep. Toxicol Rep 4:364-372.
• Kolios G, Valatas V and Ward SG (2004) Nitric oxide in inflammatory bowel disease: A universal messenger in an unsolved puzzle. Immunology 113:427-437.
• Koster-Kamphuis L, Van Straaten EA, Kors WA, De Schrijver JE, Bovee-Oudenhoven IM, Vandder Meer R and Forget PP (2003) Urinary NOx:creatinine ratios during gluten challenge in children with celiac disease. J Pediatr Gastroenterol Nutr 36:372-375.
• Lam G, Apostolopoulos V, Zulli A and Nurgali K (2015) NADPH oxidases and inflammatory bowel disease. Curr Med Chem 22:2100-2109.
• Maluf S, Pra D, Friedrisch JR, Bittar C, Da Silva MA, Henriques JA and Silla L (2009) Length of treatment and dose as determinants of mutagenicity in sickle cell disease patients treated with hydroxyurea. Environ Toxicol Pharmacol 27:26-29.
• Misra HP and Fridovich I (1972) The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 247:3170-3175.
• Murgia E, Ballardin M, Bonassi S, Rossi AM and Barale R (2008) Validation of micronuclei frequency in peripheral blood lymphocytes as early cancer risk biomarker in a nested case-control study. Mutat Res 639:27-34.
• Murray JA (1999) The widening spectrum of celiac disease. Am J Clin Nutr 69:354-365.
• Nadin SB, Vargas-Roig LM and Ciocca DR (2001) A silver staining method for single-cell gel assay. J Histochem Cytochem 49:1183-1186.
• Natarajan AT and Obe G (1980) Screening of human populations for mutations induced by environmental pollutants: use of human lymphocyte system. Ecotoxicol Environ Saf 4:468-481.
• Odetti P, Valentini S, Aragno I, Garibaldi S, Pronzato MA, Rolandi E and Barreca T (1998) Oxidative stress in subjects affected by celiac disease. Free Radic Res 29:17-24.
• Olinski R, Gackowski D, Rozalski R, Foksinski M and Bialkowski K (2003) Oxidative DNA damage in cancer patients: A cause or a consequence of the disease development? Mutat Res 531:177-190.
• Peters U, Askling J, Gridley G, Ekbom A and Linet M (2003) Causes of death in patients with celiac disease in a population-based Swedish cohort. Arch Intern Med 163:1566-1572.
• Pham-Short A, Donaghue KC, Ambler G, Garnett S and Craig ME (2016) Quality of life in type 1 diabetes and celiac Ddisease: Role of the gluten-free diet. J Pediatr 179:131-138.
• Poduri A, Evrony GD, Cai X and Walsh CA (2013) Somatic mutation, genomic variation, and neurological disease. Science 341:1237758.
• Rao TS, Currie JL, Shaffer AF and Isakson PC (1993) Comparative evaluation of arachidonic acid (AA)- and tetradecanoylphorbol acetate (TPA)-induced dermal inflammation. Inflammation 17:723-741.
• Rodrigo L (2006) Celiac disease. World J Gastroenterol 12:6585-6593.
• Ross GM, Mcmillan TJ, Wilcox P and Collins AR (1995) The single cell microgel electrophoresis assay (comet assay): Technical aspects and applications. Report on the 5th LH Gray Trust Workshop, Institute of Cancer Research, 1994. Mutat Res 337:57-60.
• Ross KA (2014) Coherent somatic mutation in autoimmune disease. PLoS One 9:e101093.
• Ryan BM and Kelleher D (2000) Refractory celiac disease. Gastroenterology 119:243-251.
• Saleh TS, Calixto JB and Medeiros YS (1996) Anti-inflammatory effects of theophylline, cromolyn and salbutamol in a murine model of pleurisy. Br J Pharmacol 118:811-819.
• Schumann M, Richter JF, Wedell I, Moos V, Zimmermann-Kordmann M, Schneider T, Daum S, Zeitz M, Fromm M and Schulzke JD (2008) Mechanisms of epithelial translocation of the alpha(2)-gliadin-33mer in coeliac sprue. Gut 57:747-754.
• See JA, Kaukinen K, Makharia GK, Gibson PR and Murray JA (2015) Practical insights into gluten-free diets. Nat Rev Gastroenterol Hepatol 12:580-591.
• Shan L, Molberg O, Parrot I, Hausch F, Filiz F, Gray GM, Sollid LM and Khosla C (2002) Structural basis for gluten intolerance in celiac sprue. Science 297:2275-2279.
• Singh NP, Mccoy MT, Tice RR and Schneider EL (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res 175:184-191.
• Sollid LM and Jabri B (2005) Is celiac disease an autoimmune disorder? Curr Opin Immunol 17:595-600.
• Sram RJ, Binkova B and Rossner Jr P (2012) Vitamin C for DNA damage prevention. Mutat Res 733:39-49.
• Stojiljkovic V, Todorovic A, Radlovic N, Pejic S, Mladenovic M, Kasapovic J and Pajovic SB (2007) Antioxidant enzymes, glutathione and lipid peroxidation in peripheral blood of children affected by coeliac disease. Ann Clin Biochem 44:537-543.
• Stojiljkovic V, Todorovic A, Pejic S, Kasapovic J, Saicic ZS, Radlovic N and Pajovic SB (2009) Antioxidant status and lipid peroxidation in small intestinal mucosa of children with celiac disease. Clin Biochem 42:1431-1437.
• Szaflarska-Poplawska A, Siomek A, Czerwionka-Szaflarska M, Gackowski D, Rozalski R, Guz J, Szpila A, Zarakowska E and Olinski R (2010) Oxidatively damaged DNA/oxidative stress in children with celiac disease. Cancer Epidemiol Biomarkers Prev 19:1960-1965.
• Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC and Sasaki YF (2000) Single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35:206-221.
• Van Heel DA and West J (2006) Recent advances in coeliac disease. Gut 55:1037-1046.
• Wilhelm Filho D, Torres MA, Marcon JL, Fraga CG and Boveris A (2000) Comparative antioxidant defenses in vertebrates - emphasis on fish and mammals. Trends Comp Biochem Physiol 7:33-45.
• Wright DH (1995) The major complications of coeliac disease. Baillieres Clin Gastroenterol 9:351-369.
• Zimmer KP, Fischer I, Mothes T, Weissen-Plenz G, Schmitz M, Wieser H, Buning J, Lerch MM, Ciclitira PC, Weber P et al. (2010) Endocytotic segregation of gliadin peptide 31-49 in enterocytes. Gut 59:300-310.

• Associate Editor: Roberto Giugliani

Publication Dates

• Publication in this collection
  10 June 2020
• Date of issue
  2020

History

• Received
  19 Jan 2019
• Accepted
  12 July 2019